“Adaptogen” has been attached to mushroom coffee, chocolate bars, sparkling water and bath salts. It has become a wellness label meaning roughly “plant, good for stress, vaguely ancient.” That is a shame, because the original concept was specific, testable and considerably more interesting than what it has become.
This piece covers where the term came from, what it was defined to mean, what research on these botanicals actually measures, and how to tell whether a product using the word has earned it.
Where the term came from
The word was coined in 1947 by Nikolai Lazarev, a Soviet toxicologist, and developed further by Israel Brekhman in the decades that followed. The context matters: this was research into how people could maintain performance under extreme conditions — cold, altitude, exhaustion, sustained physical and mental strain. It was applied work with a practical aim, not a wellness concept.
Brekhman's work centred on ginseng and on Eleutherococcus, and it produced a definition with three criteria. To qualify as an adaptogen, a substance had to:
- Be non-toxic at normal doses.
- Produce a non-specific response — increasing resistance to a broad range of stressors rather than acting on one specific problem.
- Have a normalising influence, moving the body towards balance regardless of the direction of the disturbance.
That third criterion is the strange one, and it is where much of the modern scientific scepticism sits. A substance that raises what is low and lowers what is high is a demanding thing to demonstrate, and it does not map neatly onto how pharmacology usually works.
Why the category is scientifically contested
Adaptogen is not a regulatory or clinical classification. No agency certifies a plant as one. It is a research concept from a particular tradition, and mainstream pharmacology has never fully adopted it.
The objections are reasonable. The definition is broad enough to be hard to falsify. A large share of the foundational research was published in Russian during the Soviet period and is difficult to evaluate against contemporary standards. Study quality in the modern literature varies widely, and sample sizes are often small.
None of that means the plants do nothing. It means the umbrella term carries less weight than its confident use in marketing implies, and that each botanical should be judged on its own evidence rather than on membership in a category.
What the research actually measures
Here is the part that changes how you read a label. Look at what adaptogen trials measure, and a clear pattern emerges: they overwhelmingly test performance under demand rather than enhancement at rest.
Studies on Rhodiola Rosea have been conducted in night-shift physicians, in medical students during examination periods, in people in high-stress occupational settings. The measures are fatigue scales and sustained-attention tasks — how well performance holds up across hours of demanding work.
Studies on Panax Ginseng have looked at alertness, subjective energy, calmness and working memory, again often in people under some form of ongoing load.
Nobody is running trials on well-rested volunteers on a quiet afternoon. That tells you something concrete about what to expect: if an adaptogen does anything noticeable for you, it is most likely to show up during a difficult stretch, not a comfortable one.
The single most useful reframe. Adaptogens are studied as fatigue-and-load botanicals, not as enhancement botanicals. Expecting to feel sharper on a restful Sunday is expecting something nobody has tested.
What marketing gets wrong
Four recurring problems, in rough order of how often you will meet them.
Treating the category as a guarantee
“Contains adaptogens” on a package is not a claim about effect. It is a category label with contested scientific standing. Judge the specific plant and the specific amount.
Ignoring dose entirely
A pinch of rhodiola in a chocolate bar is nothing like the standardised extract dose used in a trial. This is exactly why proprietary blends matter — if you cannot see the amount, you cannot judge whether it means anything.
Confusing the plants
Siberian ginseng (Eleutherococcus senticosus) is not ginseng. American ginseng is a different species from Asian ginseng, with a different research record. Different Rhodiola species are sometimes substituted for Rhodiola rosea, and adulteration in this market is documented. Species names matter.
Sliding towards disease claims
An adaptogen is not a treatment for anxiety, depression, burnout or chronic fatigue. Any product implying so has crossed a line, and those conditions deserve proper medical assessment rather than a botanical.
A short evaluation checklist
- Is the species named exactly? Full botanical name, not a common name.
- Is the amount disclosed? Individually, not inside a blend.
- Is the extract standardised? Rhodiola to rosavins and salidroside, ginseng to ginsenosides. Unstandardised material varies hugely by batch.
- Does the claim match the research? Fatigue and load language is consistent with the literature. Promises of transformation are not.
- Are interactions acknowledged? Rhodiola may interact with antidepressants and blood pressure medication; ginseng with diabetes medication, blood thinners and several other classes. A product that mentions none of this is not being careful with you.
Where this leaves you
Adaptogens are a genuinely interesting category with a complicated scientific standing and a research base concentrated on fatigue under demand. That is narrower than the marketing suggests and more specific than “good for stress.”
If your interest is holding performance together through a hard stretch, the research at least points in that direction. If your interest is feeling transformed on an ordinary Tuesday, no botanical in this category has been tested for that. The two adaptogens in the CogniFort formula are there for the first reason, not the second.
